China's M&A landscape may be too rich for acquisitive multinationals
This article was originally published in Clinica
Medtech multinationals that are looking to grow their presence in China through acquisitions of local players could find themselves struggling to get a good deal. Not only do buyers have to contend with the usual issues of finding the right assets that meet their specific strategic objectives, but the current climate in the Chinese financial markets means potential targets won’t come cheap.
You may also be interested in...
A $17.2m fine Chinese regulators imposed on Medtronic may just be the tip of the enforcement iceberg as the country attempts to discipline overseas manufacturers who break new antitrust laws.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.